Skip to main content

Table 4 Management of subsequent cycles of chemotherapy after low-risk FN

From: Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey

   Group ML (n = 185) Group BC (n = 160)  
   Number % Number % P-value
Q. Dose of chemotherapy      
  Dose reduction is not required 143 77 49 31 P < 0.001
  Dose reduction is required if febrile neutropenia was treated by intravenous antibiotics 18 10 56 35 P < 0.001
  Dose reduction is required at any rate 22 12 55 34 P < 0.001
  Other 2 1 0 0 P = 0.501
  Total 185 100 160 100  
Q. Antibiotics      
  Antimicrobial prophylaxis deserves consideration 67 36 42 26 P = 0.049
  Antibiotics are taken into account on the next episode of febrile neutropenia 91 49 95 59 P = 0.065
  I typically don’t administer antibiotics 27 15 23 14 P = 1
  Other 0 0 0 0 P = 1
  Total 185 100 160 100  
Q. G-CSF      
  G-CSF prophylaxis deserves consideration 47 25 26 16 P = 0.047
  G-CSF is taken into account when neutropenia occurs 114 62 75 47 P = 0.006
  G-CSF is taken into account on the next episode of febrile neutropenia 15 8 46 29 P < 0.001
  I typically don’t administer G-CSF 7 4 13 8 P = 0.107
  Other 2 1 0 0 P = 0.501
  Total 185 100 160 100